Betaine and Nonalcoholic Steatohepatitis: Back to the Future?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 Oct 13

PMID 21990946

Citations 6

Authors

Sandeep Mukherjee

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modification and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.

Citing Articles

Unveiling the crucial role of betaine: modulation of GABA homeostasis via SLC6A1 transporter (GAT1).

Bhatt M, Lazzarin E, Alberto-Silva A, Domingo G, Zerlotti R, Gradisch R Cell Mol Life Sci. 2024; 81(1):269.

PMID: 38884791 PMC: 11335192. DOI: 10.1007/s00018-024-05309-w.

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

Parameswaran M, Hasan H, Sadeque J, Jhaveri S, Avanthika C, Arisoyin A Cureus. 2022; 13(12):e20776.

PMID: 35111461 PMC: 8794413. DOI: 10.7759/cureus.20776.

Regulation of Cytochrome Oxidase by Natural Compounds Resveratrol, (-)-Epicatechin, and Betaine.

Lee I Cells. 2021; 10(6).

PMID: 34072396 PMC: 8229178. DOI: 10.3390/cells10061346.

Changes in human hepatic metabolism in steatosis and cirrhosis.

Schofield Z, Reed M, Newsome P, Adams D, Gunther U, Lalor P World J Gastroenterol. 2017; 23(15):2685-2695.

PMID: 28487605 PMC: 5403747. DOI: 10.3748/wjg.v23.i15.2685.

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M World J Gastroenterol. 2014; 20(45):16841-57.

PMID: 25492998 PMC: 4258554. DOI: 10.3748/wjg.v20.i45.16841.

References

Kathirvel E, Morgan K, Nandgiri G, Sandoval B, Caudill M, Bottiglieri T . Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol. 2010; 299(5):G1068-77. PMC: 2993168. DOI: 10.1152/ajpgi.00249.2010. View

Abdelmalek M, Angulo P, Jorgensen R, Sylvestre P, Lindor K . Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001; 96(9):2711-7. DOI: 10.1111/j.1572-0241.2001.04129.x. View

Craig S . Betaine in human nutrition. Am J Clin Nutr. 2004; 80(3):539-49. DOI: 10.1093/ajcn/80.3.539. View

Charlton M, Kasparova P, Weston S, Lindor K, Wiesner R, Rosen C . Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001; 7(7):608-14. DOI: 10.1053/jlts.2001.25453. View

Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View